← Leaderboards
Raymond Bergan
Northwestern University
$2,708,649
Attributed
$2,708,649
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2.1M · FY2014–18$2.5M$1.9M$1.3M$625K$0
'14
'15
'16
'17
'18
Funding mix
By agency
NIH$2,708,649 · 1
By mechanism
N01$2,708,649 · 1
Top collaborators
No co-investigators on record.
Most similar at Northwestern University
Same institution · by research overlap
- Seema Ahsan Khan$17,558,735
- Parambir Singh Dulai$5,769,384
Others in their field
Top investigators on “Clinical Trials”
- Lawrence Corey · Fred Hutchinson Cancer Center$824,102,536
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$622,583,125
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$542,008,718
- Bambra Strokes · Ppd Development Lp$526,656,217
- Judith S. Currier · University Of California Los Angeles$504,273,077
Research focus
Clinical TrialsUniversitiesRandomizedParticipantApoptosisMalignant NeoplasmsGene ExpressionOralAftercareBaseBiopsySafetyBiological MarkersSamplingPlacebosPlasmaTissuesBreast Cancer PreventionBreastDivision Of Cancer PreventionCell ProliferationAptamerDoseDouble-Blind Method
Grant awards (6)
INTRA- MAMMARY DISTRIBUTION OF TRANSERMAL TELAPRISTONE VERSUS ORAL TELAPRISTONE VERSUS ORAL TELAPRISTONE: A RANDOMIZED WINDOW TRAIL IN WOMEN UNDERGOING MASTECTOMY 08/26/2014 -02/25/2017$173,283
N01 · FY2018 · CA · contact PI
PROTOCOL NWU2013-02-01A PHASE I TRIAL OF INHALED ILOPROST FOR THE PREVENTION OF LUNG CANCER IN FORMER SMOKERS$461,777
N01 · FY2017 · CA · contact PI
INTRA- MAMMARY DISTRIBUTION OF TRANSERMAL TELAPRISTONE VERSUS ORAL TELAPRISTONE VERSUS ORAL TELAPRISTONE: A RANDOMIZED WINDOW TRAIL IN WOMEN UNDERGOING MASTECTOMY 08/26/2014 -02/25/2017$832,339
N01 · FY2014 · CA · contact PI
Contract HHSN261201200035I, 09/24/2012 - 09/23/2017Cancer Prevention Agent Development Program: Early Phase Clinical ResearchTask Order HHSN25100006, 09/24/2014 - 09/23/2015Core Infrastructur$618,295
N01 · FY2014 · CA · contact PI
PROTOCOL NWU2013-02-01A PHASE I TRIAL OF INHALED ILOPROST FOR THE PREVENTION OF LUNG CANCER IN FORMER SMOKERS$545,008
N01 · FY2014 · CA · contact PI
Contract HHSN261201200035I, Cancer Prevention Agent Development Program: Early Phase Clinical Research, 9/24/2012 - 9/23/2017Task Order HHSN26100005, Phase I Trial of Berberine in Subjects with U$77,947
N01 · FY2014 · CA · contact PI